This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Kiromic BioPharma マネジメント

マネジメント基準チェック /04

Kiromic BioPharma'sの CEO はPietro Bersaniで、 Jan2022年に任命され、の在任期間は 1.42年です。の年間総報酬は$ 697.49Kで、 71.2%給与と28.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.19%を直接所有しており、その価値は€ 60.70K 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と2.7年です。

主要情報

Pietro Bersani

最高経営責任者

US$697.5k

報酬総額

CEO給与比率	71.2%
CEO在任期間	1.4yrs
CEOの所有権	2.2%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	2.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Kiromic BioPharma の収益と比較して、Pietro Bersani の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$697k	US$497k	-US$35m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$336k	US$168k	-US$26m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$63k	n/a	-US$20m

報酬と市場: Pietroの総報酬 ($USD 697.49K ) は、 German市場 ($USD 406.04K ) の同規模の企業の平均を上回っています。

報酬と収益: Pietroの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Pietro Bersani (55 yo)

1.4yrs

在職期間

US$697,486

報酬

Mr. Pietro Bersani, CPA, J.D., serves as Chief Executive Officer at Kiromic BioPharma, Inc. since May 10, 2022 and serves as Director since January 27, 2022. He serves as Principal Financial Officer at Kir...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Pietro Bersani	CEO, Principal Financial Officer & Director	1.4yrs	US$697.49k	2.19% $ 60.7k
Jason Morris	Chief Financial Officer	less than a year	データなし	データなし
Leonardo Mirandola	CSO & Interim COO	less than a year	データなし	0.013% $ 373.5
Scott Dahlbeck	Chief of Staff	3.7yrs	US$442.12k	0% $ 0
Timothy Simkiss	Controller	less than a year	データなし	データなし

0.9yrs

平均在職期間

経験豊富な経営陣: 5JU0の経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Pietro Bersani	CEO, Principal Financial Officer & Director	3yrs	US$697.49k	2.19% $ 60.7k
Michael Nagel	Independent Chairperson of the Board	2.7yrs	US$214.20k	0.64% $ 17.8k
Ruggero De Maria	Member of Scientific Advisory Board	no data	データなし	データなし
Americo Cicchetti	Independent Director	3.3yrs	US$187.96k	0.64% $ 17.8k
Amorette Barber	Member of Scientific Advisory Board	no data	データなし	データなし
Martin D'Souza	Member of Scientific Advisory Board	no data	データなし	データなし
Sandeep Dhanda	Member of Scientific Advisory Board	no data	データなし	データなし
Luca Gattinoni	Member of Scientific Advisory Board	2.4yrs	データなし	データなし
Franco Locatelli	Member of Scientific Advisory Board	1.8yrs	データなし	データなし

2.7yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: 5JU0の取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

This company listing is no longer active

Kiromic BioPharma マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Recent updates

Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04